Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01263769 | Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) | completed | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04375150 | Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | completed | — | 355 | PfizerINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05485896 |
| Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC |
| completed |
| Phase 2 |
| 23 |
| Tianjin Medical University Second HospitalOTHER |
| 1 |
| Sep 19, 2024 |
| clinicaltrials |
| NCT03334344 | Using Virtual Reality (VR) Models for Preoperative Planning | completed | N/A | 92 | Ceevra, Inc.INDUSTRY | 1 | Aug 29, 2024 | clinicaltrials |
| NCT00554515 | The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma(SELECT) | completed | Phase 2 | 123 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03219333 | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer(EV-201) | completed | Phase 2 | 219 | Astellas Pharma IncINDUSTRY | 8 | Aug 27, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04316520 | Ketogenic Diet for Patients Receiving Treatment for Metastatic Renal Cell Carcinoma(CETOREIN) | completed | N/A | 20 | University Hospital, AngersOTHER_GOV | 1 | Aug 16, 2024 | clinicaltrials |
| NCT05112627 | Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy | completed | — | 15 | Mayo ClinicOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03133286 | Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)(RADIANT) | completed | — | 16 | DxTerity DiagnosticsINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06543095 | Rib Removal and Pain in Partial Nephrectomy | completed | — | 50 | TC Erciyes UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06531629 | Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients | completed | — | 72,408 | Peking University First HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06525467 | Primary Renal Lymphoma on a 48 Year Old Woman | completed | — | 1 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04669366 | Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries | completed | — | 1,205 | PfizerINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03200587 | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | completed | Phase 1 | 12 | University of UtahOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03819569 | GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses(GRADE-SRM) | completed | N/A | 265 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03829111 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | completed | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT00026663 | Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance | completed | — | 86 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2024 | clinicaltrials |
| NCT01326871 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | completed | Phase 1 / Phase 2 | 68 | Altor BioScienceINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT01002937 | Novel Prognostic Markers in Renal Cancer | completed | — | 182 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | completed | Phase 1 | 22 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT03776123 | Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients | completed | — | 347 | IpsenINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT04604158 | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | completed | N/A | 38 | Gillian GreshamOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT00831857 | VEGF Imaging in Renal Cell Carcinoma(Renimage) | completed | — | 26 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01028638 | Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma(Everolimage) | completed | — | 13 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01398306 | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.(BANN) | completed | — | 40 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03097328 | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Bradley A. McGregor, MDOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT01931644 | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | completed | — | 17,667 | Sanguine BiosciencesINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06369519 | Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma | completed | — | 3,677 | Peking University First HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05375136 | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients | completed | — | 135 | Eisai Korea Inc.INDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06317207 | Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy(LiangAH) | completed | — | 15 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 0 | Mar 19, 2024 | clinicaltrials |
| NCT02762006 | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | completed | Phase 1 | 29 | Moshe OrnsteinOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | completed | Phase 2 | 26 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06214000 | Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney(LiVHOU) | completed | — | 178 | University Hospital, Strasbourg, FranceOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT02156895 | Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | completed | — | 111 | PfizerINDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04834778 | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | completed | Phase 1 | 23 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02527304 | Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery | completed | N/A | 24 | Albert Einstein College of MedicineOTHER | 1 | Mar 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials